Home › Research › Getting a diagnosis
Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Patients with Alzheimer’s Disease and Other Dementias: A Center-Based Study
Francesca de Rino, Francesca Rispoli, Marta Zuffi, Eleonora Matteucci, Armando Gavazzi, Michela Salvatici, Delia Francesca Sansico, Giulia Pollaroli et al.. International Journal of Molecular Sciences, 2025-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Neuropsychological interviews and neuroimaging techniques are traditional diagnostic methods for Alzheimer's disease (AD). However, the development of blood-based biomarkers, such as Amyloid beta (Aβ), phosphorylated Tau (pTau), and their ratios, offers promising non-invasive alternatives for early AD detection. This study aimed to analyze the correlation between CSF and plasma biomarkers (Aβ40, Aβ42, Aβ42/Aβ40, pTau181) and evaluate their diagnostic performance in 51 patients with cognitive impairments. Biomarkers were analyzed in both plasma and CSF using an automated chemiluminescence enzyme immunoassay, Lumipulse (Fujirebio). The results showed significant positive correlations between CSF and plasma levels of Aβ42, the Aβ42/Aβ40 ratio, and pTau181, but not for Aβ40. Plasma Aβ42, pTau181, Aβ42/Aβ40 ratio, and pTau181/Aβ42 ratio demonstrated significant differences between patients A+ vs. A- classified based on CSF Amyloid status, as well as between those classified as A+T+ and A-T- according to both CSF Amyloid and Tau levels. Plasma pTau181, Aβ42/Aβ40, and pTau181/Aβ42 ratio showed high diagnostic accuracy in distinguishing A+ from A- (AUC = 0.93-0.95) and A+T+ from A-T- patients (AUC = 0.93-0.97). These findings suggest that plasma biomarkers can effectively differentiate between AD and other forms of dementia, and serve as a reliable, non-invasive tool for early detection and monitoring of Alzheimer's disease.
What this study adds
Evidence grade: Low
The record lists 51 participants. In 51 patients with cognitive impairments, plasma levels of Aβ42, pTau181, and their ratios correlated with CSF levels and showed high accuracy in distinguishing amyloid-positive from amyloid-negative patients. Reported effect size: AUC = 0.93-0.95; AUC = 0.93-0.97.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
de Rino, F., Rispoli, F., Zuffi, M., Matteucci, E., Gavazzi, A., Salvatici, M., et al. (2025). Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Patients with Alzheimer’s Disease and Other Dementias: A Center-Based Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094308
Vancouver
de Rino F, Rispoli F, Zuffi M, Matteucci E, Gavazzi A, Salvatici M, et al. Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Patients with Alzheimer’s Disease and Other Dementias: A Center-Based Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094308. PMID: 40362548.
BibTeX
@article{derino2025-40362548,
author = {de Rino, Francesca and Rispoli, Francesca and Zuffi, Marta and Matteucci, Eleonora and Gavazzi, Armando and Salvatici, Michela and Sansico, Delia Francesca and Pollaroli, Giulia and others},
title = {{Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Patients with Alzheimer’s Disease and Other Dementias: A Center-Based Study}},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094308},
pmid = {40362548},
url = {https://doi.org/10.3390/ijms26094308}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The results showed significant positive correlations between CSF and plasma levels of Aβ42, the Aβ42/Aβ40 ratio, and pTau181, but not for Aβ40.
- Plasma Aβ42, pTau181, Aβ42/Aβ40 ratio, and pTau181/Aβ42 ratio demonstrated significant differences between patients A+ vs.
- These findings suggest that plasma biomarkers can effectively differentiate between AD and other forms of dementia, and serve as a reliable, non-invasive tool for early detection and monitoring of Alzheimer's disease.
Why it matters
In 51 patients with cognitive impairments, plasma levels of Aβ42, pTau181, and their ratios correlated with CSF levels and showed high accuracy in distinguishing amyloid-positive from amyloid-negative patients. This supports plasma biomarkers as a non-invasive tool for early detection, but it does not treat, cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Participants51
- Effect sizeAUC = 0.93-0.95; AUC = 0.93-0.97
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International Journal of Molecular Sciences) |
| Journal's citation record | 3 / 4 | International Journal of Molecular Sciences: journal h-index 426 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 51 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Lorenzo Drago: h-index 60 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Milan: institution h-index 1,023 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40362548) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3390/ijms26094308
- PubMed: 40362548
- Original source →
- Free full text: International Journal of Molecular Sciences →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Getting a diagnosis from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.